Home › NCT07322445
Multi-modal Imaging of Myofascial Pain - Phase 2
Recruiting
Development and Identification of Magnetic Resonance, Electrophysiological, and Fiber-optic Imaging Biomarkers of Myofascial Pain
Who can join
Ages 18 to 80 · All sexes
Full eligibility criteria
Inclusion Criteria: 1. Adults between the ages of 18 and 80 years old. 2. History of spontaneous (non-provoked) pain in the neck and/or shoulder region lasting at least 3 months. Neck and/or shoulder pain, unilateral or bilateral. 3. Presence of a palpable myofascial trigger point (MTrP) in one or both upper trapezius muscles. 4. The participant has a Numeric Pain Rating Scale of 4/10 or more in the last one week, and the pain is reproducible by palpating the trigger point. 5. Pain localized to the area of the trigger point that is reproduced or worsened upon palpation. 6. Radiation of pain to the head, neck, or face with palpation is allowed but not required. Exclusion Criteria: 1. Age \<18 or \>80 years old. 2. Acute cervical spine pathology, trauma (e.g. whiplash) or cervical radiculopathy 3. History of surgery involving the head, neck, or shoulder girdle. 4. Presence of neuromuscular pathologies or inflammatory muscle diseases (e.g. dermatomyositis) 5. Systemic disease with diffuse body pain (e.g. system lupus erythematosus) 6. Peripheral neuropathy 7. Cancer-related pain 8. Pregnancy, coagulopathy or other bleeding disorder, fever, general/local infection at the pain site, substance abuse, or any other diseases that may account for signs and symptoms mimicking myofascial pain. 9. Contraindication to MRI 10. Chronic fatigue syndrome, fibromyalgia, or chronic Lyme disease. 11. Use of acupuncture or changes in pain medications within 6 weeks of enrollment. 12. Receipt of Botox injection to the neck/shoulder region within the past 3 months or trigger point injection within the past 6 weeks.
About the study
The goal of this study is to evaluate imaging biomarkers for quantitative assessments of myofascial pain and determine their ability to monitor treatment response and predict clinical outcomes.
What is being tested
- 50/50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution (drug)
- Dry Needling (procedure)
Sponsor: Washington University School of Medicine · Participants: 100 · Started: Oct 24, 2023
Contact the study team
- Andre Guthrie, BS · Phone: 3142732556
Official record on ClinicalTrials.gov — NCT07322445
Locations in the U.S.
| Missouri | Washington University, St Louis |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.